Patterns of Prescription Discontinuation, Reinitiation, and Switching of Subcutaneous Semaglutide and Tirzepatide in Adults With Obesity
- Design
- Retrospective cohort
- Drugs
- Semaglutide, Tirzepatide
- Assessment
- Facts extracted automatically · reviewed by Carrie Schluter, Nov 5, 2026 · added Nov 6, 2026
This study was added automatically, and its details were extracted by machine rather than read off the paper by a person. Carrie Schluter has reviewed the record, but that review did not re-extract those details, so the collection still publishes no population match, weight-loss explanation, study tier, findings, population or funding details for it: a check of automatically extracted details found too many errors to show them as fact. The abstract below is the source as retrieved.
01Source
The source, as retrieved
Abstract
[OBJECTIVE] Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs), such as semaglutide, and dual GLP-1/glucose-dependent insulinotropic polypeptide RAs, such as tirzepatide, are increasingly used for obesity management. However, real-world patterns of discontinuation, reinitiation, and switching among individuals without diabetes remain poorly described. This study describes the real-world patterns of discontinuation and reinitiation of subcutaneous semaglutide and tirzepatide in adults with obesity but without diabetes in an academic medical center. Secondary objectives included evaluating transitions between semaglutide and tirzepatide and switches from these agents to first-generation antiobesity medications (AOMs). [RESEARCH DESIGN AND METHODS] A retrospective cohort study of adults with obesity but without diabetes who were prescribed semaglutide or tirzepatide was conducted using electronic health record data. Patterns of discontinuation, reinitiation, and switching (change from one agent to another or to a first-generation AOM) were assessed over 12 months. [RESULTS] Among 9,189 adults initiating subcutaneous semaglutide or tirzepatide, 36.7% of the sample had a prescription that lasted <32 days (mean, 3.6 days), with 82.7% receiving no further prescriptions for AOMs that year. Prescription coverage was 32-179 days and 180-335 days in 27.0% and 17.7% of participants, respectively, with most (72.3% and 89.5%) not having any prescriptions for AOMs thereafter. Persistent prescriptions (coverage for ≥336 days) were observed in 18.6% of participants. Prescriptions to reinitiate or switch to another GLP-1 RA or first-generation AOM were rare. [CONCLUSIONS] In a real-world academic setting, a substantial proportion of individuals with obesity, but without diabetes, discontinued GLP-1-based treatments.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Oct 25, 2026 | 42920957 first ingestion |
| pubmed | Nov 1, 2026 | 42920957 duplicate matched on doi |
| owner-review | Nov 6, 2026 | reviewed_by set to Carrie Schluter (2026-11-05) on the owner's own confirmation. The assessment is unchanged and still the auto-classifier's, so its extracted values stay withheld under the 2026-10-18 decision. |
| reextract | Nov 6, 2026 | manufacturer: 'Novo Nordisk, Eli Lilly, Lilly, Boehringer Ingelheim' -> None. Q-043: manufacturer and drug_details.dose re-extracted by auto-classifier-v1.2. manufacturer no longer reads companies named only in the authors' conflicts statement (IN-062) and refuses a multi-company roster; dose is tied to the GLP-1 agent by name, never reads a concentration, and records a multi-dose design whole. Every other value is carried forward unchanged. Owner decision IN-064 option 1, 2026-11-06. |
| pubmed | Nov 8, 2026 | 42920957 duplicate matched on doi |